Clinical Trial Update: Pembrolizumab, Ibrutinib and Rituximab in PCNSL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study of pembrolizumab, ibrutinib, and rituximab in primary central nervous system lymphoma (PCNSL) that …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Pembrolizumab (pembrolizumab)
• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Primary Central Nervous System Lymphoma, Recurrent Cancer | Phase 1, Phase 2 | Status: RECRUITING